Is Erdafitinib effective in the treatment of urothelial cancer?

Erdafitinib is an oral FGFR (fibroblast growth factor receptor) inhibitor designed to treat patients with urothelial cancer who carry FGFR gene mutations or fusions. Urothelial carcinoma is a common malignant tumor of the urinary system. Some patients have FGFR gene abnormalities that drive the occurrence and development of tumors. Erdafitinib exerts anti-tumor effects by selectively inhibiting the FGFR signaling pathway and blocking tumor cell proliferation and angiogenesis.

Multiple clinical trial results have shown that erdafitinib has significant efficacy in patients with locally advanced or metastatic urothelial carcinoma carrying FGFR2 or FGFR3 mutations. The drug can significantly extend patients' progression-free survival (PFS) and overall survival (OS), while improving patients' quality of life. Especially for patients who have previously received chemotherapy and whose disease has progressed, erdafitinib provides an effective treatment option and fills this clinical gap.

The efficacy of erdafitinib is not only reflected in tumor control, but also shows good tolerability. Common side effects include stomatitis, blurred vision, rash, and electrolyte imbalance, and most patients can be controlled through dose adjustment and symptomatic treatment. Patients need to regularly monitor blood biochemical indicators and vision conditions during use to ensure medication safety.

In general, erdafitinib, as the first targeted drug approved for FGFR gene mutation-positive urothelial cancer, brings new treatment hope to this type of patients. Its precise targeting mechanism and good efficacy make it one of the important choices for the treatment of urothelial cancer, promoting the development of personalized precision medicine.

Reference materials:https://www.drugs.com